Samrat Pharmachem Limited (BOM:530125)
India · Delayed Price · Currency is INR 198.75
0.00 (0.00%)
At close: Jun 19, 2026
Samrat Pharmachem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 2,897 | 2,859 | 2,816 | 3,106 | 2,218 |
Other Revenue | - | 0.68 | 0.57 | 0.99 | 1.07 |
| 2,897 | 2,859 | 2,816 | 3,107 | 2,219 | |
Revenue Growth (YoY) | 1.33% | 1.52% | -9.37% | 40.06% | 23.83% |
Cost of Revenue | 2,830 | 2,667 | 2,703 | 2,779 | 1,899 |
Gross Profit | 66.75 | 191.83 | 113.21 | 328.8 | 319.58 |
Selling, General & Admin | 22.76 | 25.35 | 23.62 | 20.51 | 18.37 |
Other Operating Expenses | 65.38 | 62.39 | 64.46 | 67.99 | 57.48 |
Operating Expenses | 95.34 | 94.28 | 94.55 | 94.94 | 81.8 |
Operating Income | -28.59 | 97.54 | 18.66 | 233.86 | 237.78 |
Interest Expense | -9.55 | -4.86 | -5.53 | -9.3 | -3.64 |
Interest & Investment Income | - | 3.69 | 3.05 | 2 | 1.38 |
Currency Exchange Gain (Loss) | - | 0.6 | 0.32 | 1.53 | 0.6 |
Other Non Operating Income (Expenses) | 8.34 | -1.21 | -1.35 | -3.02 | -0.18 |
EBT Excluding Unusual Items | -29.81 | 95.76 | 15.15 | 225.07 | 235.94 |
Gain (Loss) on Sale of Investments | - | 4.05 | 9.87 | 0.23 | 0.08 |
Gain (Loss) on Sale of Assets | - | -0.95 | 0.18 | - | -0.23 |
Pretax Income | -29.81 | 98.86 | 25.2 | 225.3 | 236.01 |
Income Tax Expense | 3.31 | 27.74 | 3.58 | 59 | 64.16 |
Net Income | -33.12 | 71.12 | 21.63 | 166.31 | 171.85 |
Net Income to Common | -33.12 | 71.12 | 21.63 | 166.31 | 171.85 |
Net Income Growth | - | 228.87% | -87.00% | -3.23% | 222.22% |
Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 |
Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 |
Shares Change (YoY) | -0.01% | - | - | - | - |
EPS (Basic) | -10.72 | 23.02 | 7.00 | 53.83 | 55.62 |
EPS (Diluted) | -10.72 | 23.02 | 7.00 | 53.83 | 55.62 |
EPS Growth | - | 228.87% | -87.00% | -3.23% | 222.25% |
Free Cash Flow | 57.84 | -105.99 | 87.45 | -108.96 | 161.98 |
Free Cash Flow Per Share | 18.72 | -34.30 | 28.30 | -35.27 | 52.42 |
Dividend Per Share | - | 1.000 | 1.000 | 1.000 | 1.000 |
Gross Margin | 2.30% | 6.71% | 4.02% | 10.58% | 14.40% |
Operating Margin | -0.99% | 3.41% | 0.66% | 7.53% | 10.72% |
Profit Margin | -1.14% | 2.49% | 0.77% | 5.35% | 7.75% |
Free Cash Flow Margin | 2.00% | -3.71% | 3.10% | -3.51% | 7.30% |
EBITDA | -21.4 | 104.08 | 25.12 | 240.28 | 243.71 |
EBITDA Margin | -0.74% | 3.64% | 0.89% | 7.73% | 10.98% |
D&A For EBITDA | 7.2 | 6.53 | 6.46 | 6.42 | 5.94 |
EBIT | -28.59 | 97.54 | 18.66 | 233.86 | 237.78 |
EBIT Margin | -0.99% | 3.41% | 0.66% | 7.53% | 10.72% |
Effective Tax Rate | - | 28.06% | 14.19% | 26.19% | 27.19% |
Revenue as Reported | 2,906 | 2,868 | 2,830 | 3,111 | 2,224 |
Advertising Expenses | - | 3.14 | 1.43 | 1.72 | 0.62 |